Reata Pharmaceuticals Inc (RETA) Stock
RETA is no longer traded. Reata Pharmaceuticals was acquired by Biogen (BIIB) on September 26, 2023.
Each RETA share was exchanged for $172.50 in cash. Prices on this page are historical; the last trade was September 25, 2023 at $172.36.
See Biogen (BIIB) stock →Reata Pharmaceuticals stock price history
RETA final trading statistics
- Final close
- $172.36
- Final trading day
- Sep 25, 2023
- Market cap at delisting
- $5.79B
- Shares outstanding
- 33.59M
- Final 52-week range
- $21.83 – $172.46
- Avg. volume (final 3 mo.)
- 978,820
- All-time high (split-adj.)
- $247.74 · Feb 2020
- All-time low (split-adj.)
- $13.07 · May 2016
- Return since IPO
- +1218.7%
- Beta
- 1.42
- Book value / share
- $2.31
- Price / book
- 74.74
Reata Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $2.22M | -$311.9M | -$8.54 |
| FY2021 | $11.49M | -$297.4M | -$8.18 |
| FY2020 | $9.02M | -$247.8M | -$6.98 |
| FY2019 | $26.52M | -$290.2M | -$5.03 |
| FY2018 | $53.59M | -$80.5M | -$2.86 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Reata Pharmaceuticals Inc
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. As of September 26, 2023, Reata Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.
Reata Pharmaceuticals stock FAQ
What happened to Reata Pharmaceuticals stock?
Reata Pharmaceuticals was acquired by Biogen (BIIB) on September 26, 2023. Shareholders received $172.50 in cash for each share. RETA stock stopped trading on the Nasdaq, with a final close of $172.36 on September 25, 2023.
What did Reata Pharmaceuticals shareholders receive?
Each RETA share was converted into $172.50 in cash. The deal was valued at about $7.3 billion.
Is RETA stock still trading?
No. RETA was delisted from the Nasdaq on September 26, 2023 and no longer trades on a U.S. exchange.
What was the last price of RETA stock?
RETA closed at $172.36 on its final trading day, September 25, 2023, for a market value of about $5.79B.
What were Reata Pharmaceuticals's revenue and earnings in its last full fiscal year?
Reata Pharmaceuticals reported revenue of $2.22M and net income of -$311.9M in fiscal 2022, its last full year as a public company.
When did Reata Pharmaceuticals go public?
Reata Pharmaceuticals Inc stock began trading on May 26, 2016.